Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Quantum Biopharma ( (TSE:QNTM) ) is now available.
On October 14, 2025, Quantum BioPharma Ltd. issued a response to allegations made by The Schall Law Firm and DJS Law Group regarding potential securities law violations. The company refutes these claims as vague and unsubstantiated, viewing them as opportunistic litigation tactics. Quantum BioPharma is reviewing the conduct of the law firms involved and intends to take appropriate action to protect its reputation. This announcement highlights the company’s proactive stance in addressing legal challenges and maintaining its market integrity.
More about Quantum Biopharma
Quantum BioPharma Ltd. is a biopharmaceutical company focused on developing innovative biotech solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. The company is advancing drug candidates at various development stages and owns a subsidiary, Lucid Psycheceuticals Inc., which is working on a compound for multiple sclerosis. Quantum BioPharma also has a stake in Unbuzzd Wellness Inc., which markets an OTC product, and maintains strategic investments through its subsidiary, FSD Strategic Investments Inc.
Average Trading Volume: 4,076
Technical Sentiment Signal: Sell
Current Market Cap: C$77.84M
For an in-depth examination of QNTM stock, go to TipRanks’ Overview page.